Nav: Home

Reducing the burden of tuberculosis treatment

March 13, 2019

CAMBRIDGE, MA -- Tuberculosis is one of the world's deadliest infectious diseases: One-third of the world's population is infected with TB, and more than 1 million people die from the disease every year.

One reason TB is so pervasive is that treatment requires a six-month course of daily antibiotics, which is difficult for about half of all patients to adhere to, especially in rural areas with limited access to medical facilities. To help overcome that, a team of researchers led by MIT has devised a new way to deliver antibiotics, which they hope will make it easier to cure more patients and reduce health care costs.

Using this new approach, a coiled wire loaded with antibiotics is inserted into the patient's stomach through a nasogastric tube. Once in the stomach, the device slowly releases antibiotics over one month, eliminating the need for patients to take pills every day.

"Having a system that allows you to ensure the patient receives the full treatment course could be really transformational," says Giovanni Traverso, an assistant professor in MIT's Department of Mechanical Engineering and a gastroenterologist at Brigham and Women's Hospital. "When you consider the situation with tuberculosis, where you have multiple grams of antibiotics that have to be taken every day, for many months, we need another solution."

Traverso and Robert Langer, the David H. Koch Institute Professor at MIT, are the senior authors of the study, which appears in the March 13 issue of Science Translational Medicine and includes a full list of authors. The paper's lead author is MIT graduate student Malvika Verma; the team includes others at MIT, as well as researchers from Harvard Medical School, Boston University School of Public Health, several hospitals in India, and the Tata Trusts of Mumbai, India.

Long-term delivery

For several years, Traverso and Langer have been working on a variety of pills and capsules that can remain in the stomach and slowly release medication after being swallowed. This kind of drug delivery, they believe, could improve treatment for many chronic diseases that require daily doses of medication.

One of their capsules has shown promise for delivering small amounts of drugs to treat HIV and malaria. After being swallowed, the capsule's outer coating dissolves, allowing six arms to expand, helping the device to lodge in the stomach. This device can carry about 300 milligrams of drugs -- enough for a week's worth of HIV treatment, for example. However, it falls far short of the payload needed to treat tuberculosis, which requires about 3 grams of antibiotics every day.

"We had to develop a completely new system that could enable an automated release of these medications over the course of about a month," Verma says. "This new system can hold a lot more drug and it can release the drug for a longer period of time."

The new device is a thin, elastic wire made of nitinol -- an alloy of nickel and titanium that can change its shape based on temperature. The researchers can string up to 600 "pills" of various antibiotics along the wire, and the drugs are packaged in polymers whose composition can be tuned to control the rate of drug release once the device enters the stomach.

The wire is delivered to the patient's stomach via a tube inserted through the nose, which is used routinely in hospitals for delivering medications and nutrients. As part of their study, the researchers interviewed 300 tuberculosis patients in India, and most said that this kind of delivery would be acceptable to them for long-term treatment.

"In many cases, this was preferred by the patients, who could come to a health care setting every two weeks or every four weeks instead of having to be seen by a health care provider every day," Traverso says.

Once the wire reaches the higher temperatures of the stomach, it forms a coil, which prevents it from passing further through the digestive system. In tests in pigs, the researchers found that their prototype device could release several different antibiotics at a constant rate for 28 days. Once all of the drugs are delivered, the device is retrieved through the nasogastric tube using a magnet that can attract the coil.

Cost reduction

The research team included an economist, David Collins of Boston University, who analyzed the potential economic impact of this type of treatment. He found that if implemented in India, treatment costs could be reduced by about $8,000 per patient.

"The current model for TB treatment is directly observed treatment, short course, where the patients have to come in every day and have somebody watch them take their pills. That's a huge burden, for the patients and the health care system," Verma says. "We envision this as utilizing the infrastructure of the directly observed treatment, but reducing the frequency of administering the treatment from daily to monthly."

Another disease where this approach could be useful is hepatitis C, which requires treatment with antiviral drugs for two to six months. Many other infectious diseases also require doses of medication that are too large to fit in one of the smaller, ingestible devices that Traverso and Langer have developed.

"In many situations, patients need to take multigram dosages of a drug, but up until now, this has been very difficult to do," Langer says. "We believe that this new approach is an important milestone toward addressing this problem."

This system might also be useful for delivering drugs that can treat alcohol addiction and other types of substance abuse, the researchers say.
-end-
The research was funded by the Bill and Melinda Gates Foundation, the National Institutes of Health, the MIT Tata Center, the National Science Foundation, the Alexander von Humboldt Foundation, and the Division of Gastroenterology at Brigham and Women's Hospital.

Massachusetts Institute of Technology

Related Tuberculosis Articles:

Tuberculosis: New insights into the pathogen
Researchers at the University of Würzburg and the Spanish Cancer Research Centre have gained new insights into the pathogen that causes tuberculosis.
Unmasking the hidden burden of tuberculosis in Mozambique
The real burden of tuberculosis is probably higher than estimated, according to a study on samples from autopsies performed in a Mozambican hospital.
HIV/tuberculosis co-infection: Tunneling towards better diagnosis
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS.
Reducing the burden of tuberculosis treatment
A research team led by MIT has developed a device that can lodge in the stomach and deliver antibiotics to treat tuberculosis, which they hope will make it easier to cure more patients and reduce health care costs.
Tuberculosis: Commandeering a bacterial 'suicide' mechanism
The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote protein.
A copper bullet for tuberculosis
Tuberculosis is a sneaky disease, and the number one cause of death from infectious disease worldwide.
How damaging immune cells develop during tuberculosis
Insights into how harmful white blood cells form during tuberculosis infection point to novel targets for pharmacological interventions, according to a study published in the open-access journal PLOS Pathogens by Valentina Guerrini and Maria Laura Gennaro of Rutgers New Jersey Medical School, and colleagues.
How many people die from tuberculosis every year?
The estimates for global tuberculosis deaths by the World Health Organisation (WHO) and the Institute for Health Metrics and Evaluation (IHME) differ considerably for a dozen countries, according to a study led by ISGlobal.
Beyond killing tuberculosis
Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease.
Tuberculosis drugs work better with vitamin C
Studies in mice and in tissue cultures suggest that giving vitamin C with tuberculosis drugs could reduce the unusually long time it takes these drugs to eradicate this pathogen.
More Tuberculosis News and Tuberculosis Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.